Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bivalent oral poliovirus vaccine + DTP-HB-Hib vaccine + inactivated poliovirus vaccine
- Development stage
- Unknown
- Lead developer
- Bio Farma
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Oral, Intramuscular
01
Overview
The regimen 'bivalent oral poliovirus vaccine (bOPV) + DTP-HB-Hib vaccine + inactivated poliovirus vaccine (IPV)' is a combination immunization schedule developed by PT Bio Farma. It was specifically evaluated in Indonesian infants to facilitate the global transition from trivalent oral poliovirus vaccine (tOPV) to a schedule using bOPV and IPV. The regimen includes Bio Farma's bOPV (containing live attenuated poliovirus types 1 and 3), the pentavalent vaccine Pentabio® (containing diphtheria toxoid, tetanus toxoid, whole-cell pertussis, hepatitis B surface antigen, and Haemophilus influenzae type b conjugate), and a standalone IPV (providing inactivated poliovirus types 1, 2, and 3). This comprehensive schedule provides protection against poliomyelitis, diphtheria, tetanus, pertussis, hepatitis B, and Hib-related diseases.
- Brand names
- PentabioBio Farma bOPV
- Other names
- bOPV + DTP-HB-Hib + IPVbOPV + Pentabio + IPVbivalent oral poliovirus vaccine plus Pentabio plus inactivated poliovirus vaccine
02
Targets
HBsAg (Hepatitis B surface antigen)TT (Tetanus toxoid)PV3 (Sabin) (Poliovirus type 3 antigen)
Beyond the preview
Go deeper on bivalent oral poliovirus vaccine + DTP-HB-Hib vaccine + inactivated poliovirus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bivalent oral poliovirus vaccine + DTP-HB-Hib vaccine + inactivated poliovirus vaccine.